Multiple Sclerosis

New study removes cancer doubt for multiple sclerosis drug

 

London, UK (October 1,  2015) – Researchers from Queen Mary University of London (QMUL) are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis (MS) after new evidence shows it does not increase the risk of cancer as previously thought.


The drug called Cladribine is already licensed and in use for people with leukemia, a blood disease. Previous studies, ran with patients at Barts Health NHS Trust in London, showed Cladribine to be highly effective in treating relapsing MS. One trial showed the drug reduced relapses by over 50 per cent, and nearly 50 percent of people showed no signs of disease activity at all over two years. However, Cladribine was refused market authorisation on the suspicion it may cause cancer based on the interpretation of previous data.

 

A new study published in the journal Neurology: Neuroimmunology & Neuroinflammation* compared the incidence of cancer where patients had been treated with Cladribine to other studies where they had been treated with other similar drugs that are currently licensed for MS.

 

The team from the Blizard Institute at QMUL compared data from the 11 pivotal trials that were used to support the licensing of seven different drugs to examine the cancer risk. They found there was no evidence for an increased risk of cancer in people with MS taking Cladribine.

 

Cladribine appears to be more effective, safer, easier to use and could potentially be cheaper than other current drugs used to treat MS.

 

"Our research shows that clinical academics and drug makers should continue to develop Cladribine for people with relapsing MS as the risk of developing cancer is no greater than for other types of current medication," said Dr Klaus Schmierer, lead author and Reader in Clinical Neurology at QMUL and Consultant Neurologist at Barts Health NHS Trust.

 

He added: "As well as being easier and cheaper to administer, Cladribine benefits female patients who want to get pregnant. Other drugs used to treat relapsing MS need to be stopped during pregnancy and that can expose women to increased risk of MS disease activity. That’s not the case with Cladribine, which has a long lasting effect."

 

It is estimated that over 120,000 people with MS live in the UK and it affects over two million patients globally. MS, which is a chronic, inflammatory condition of the central nervous system affects young adults and has a substantial impact on quality of their life, employment, and relationships.

 

 


Queen Mary, University of London, 01.10.2015.

MEDICAL NEWS

Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…

SCHMERZ PAINCARE

Wie ein Schmerz den anderen unterdrückt
Opioidtherapien im palliativen Praxisalltag: Retardierte Analgetika zeigen Vorteile
Krankenhäuser und Praxen müssen sich bei der Schmerztherapie nach Operationen…
Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle

DIABETES

Typ-2-Diabetes: Neue Hinweise bestärken die Bedeutung von Übergewicht für Spätfolgen
Suliqua®: Eine sinnvolle Option, wenn die BOT zur Blutzuckerkontrolle nicht…
„Körperstolz“: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Bestmögliche Versorgungssicherheit bei der Krebstherapie mit CAR-T-Zellen
Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Neue Darreichungsform zur Antiemese bei Chemotherapie: Akynzeo® ist ab sofort…

MULTIPLE SKLEROSE

Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei aktiver…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…